On December 21, 2023, Catherine Friedman informed Seer, Inc. of her resignation as a member of the Company?s Board of Directors and all committees thereof, effective immediately. In connection with Ms. Friedman?s resignation from the Board, the size of the Board was decreased from eight to seven members. Also, following Ms. Friedman?s resignation, the Board appointed Rachel Haurwitz, Ph.D. to the Audit Committee of the Board (the ?Audit Committee?) and appointed Meeta Gulyani as the Chair of the Audit Committee.
The Board determined that Dr. Haurwitz qualifies as independent under the director independence standards set forth in the rules and regulations of Securities and Exchange Commission (the ?SEC?) and the applicable listing standards of the Nasdaq Stock Market (?Nasdaq?) and also satisfies the additional requirements of financial literacy and audit committee independence for audit committee service under the applicable rules and regulations of the SEC and listing standards of Nasdaq. The Board determined that Dr. Haurwitz qualifies as an ?audit committee financial expert? within the meaning of SEC rules and regulations.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
SEER, INC. 
